Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-6552 effects on sleep latency in sleep-deprived healthy participants
NCT06619665Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MK-6552 in narcolepsy (6 arms), sponsored by Merck & Co. Primary endpoints: Participants with an Adverse Event, Participants who discontinued from study due to an AE at Day 1 and 1 more. Started Mar 2024; status: completed.
02
Drugs
MK-6552
03
Conditions
narcolepsy
Beyond the preview
Go deeper on NCT06619665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06619665.